Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Spiros Stratigis

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Kidney Diseases (Basel, Switzerland)|August 19, 2016
Potassium: From Physiology to Clinical ImplicationsMiriam Zacchia, Maria Luisa Abategiovanni, Spiros Stratigis, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|July 9, 2013
[Inhibitors of intra-cystic secretion: novel therapies in ADPKD (Autosomal Dominant Polycystic Kidney Disease)]Nunzia Miranda, Francesca Miranda, Luca Rinaldi, et al.
Current Therapeutic Research, Clinical and Experimental|March 28, 2014
Unit dosing of darbepoetin alfa for thetreatment of anemia in patients with end-stage renal disease being switched from recombinant human erythropoietin: Results of a phase IIIb, 27-week, multicenter, open-label study in Greek patientsGeorgios Bristoyiannis, Nikolaos Germanos, Dimitrios Grekas, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Kidney Diseases (Basel, Switzerland)|August 19, 2016
Potassium: From Physiology to Clinical ImplicationsMiriam Zacchia, Maria Luisa Abategiovanni, Spiros Stratigis, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|July 9, 2013
[Inhibitors of intra-cystic secretion: novel therapies in ADPKD (Autosomal Dominant Polycystic Kidney Disease)]Nunzia Miranda, Francesca Miranda, Luca Rinaldi, et al.
Current Therapeutic Research, Clinical and Experimental|March 28, 2014
Unit dosing of darbepoetin alfa for thetreatment of anemia in patients with end-stage renal disease being switched from recombinant human erythropoietin: Results of a phase IIIb, 27-week, multicenter, open-label study in Greek patientsGeorgios Bristoyiannis, Nikolaos Germanos, Dimitrios Grekas, et al.
Pageof 1